BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Oxaliplatin: trial readouts and FDA decisions

6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 8 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Qilu Pharmaceutical Co., Ltd., Arcus Biosciences, Inc., Suzhou Suncadia Biopharmaceuticals Co., Ltd., AskGene Pharma, Inc., CStone Pharmaceuticals, FutureGen Biopharmaceutical (Beijing) Co., Ltd, Akeso, Taiho Oncology, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerOvarian Cancerrecruiting150
2026-12 est.P2Qilu Pharmaceutical Co., Ltd.NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or GastroesophagGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinomanot yet recruiting100
2026-12-30 est.P3AskGene Pharma, Inc.NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaGastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinomaactive not recruiting780
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01-11 est.P3FutureGen Biopharmaceutical (Beijing) Co., LtdNCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable orLocally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastarecruiting486
2027-01-13 est.P3AkesoNCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal CancerColorectal Adenocarcinomarecruiting560

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-10 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07256782 A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsAdvanced Solid Tumorrecruiting444
2026-10 est.P2Qilu Pharmaceutical Co., Ltd.NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerCLDN18.2-positive Advanced Biliary Tract Cancernot yet recruiting120
2026-09-07P2Arcus Biosciences, Inc. RCUSNCT05329766 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignancieGastrointestinal Tract Malignanciescompleted332
2026-08-28P3Arcus Biosciences, Inc. RCUSNCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That CAdvanced Upper Gastrointestinal Tract Adenocarcinomacompleted1040
2026-07-15P3Jazz Pharmaceuticals JAZZNCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinomaactive not recruiting920
2026-06-30 est.P2Qilu Pharmaceutical Co., Ltd.NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsAdvanced Solid Tumornot yet recruiting360
2026-06 est.P3Revolution Medicines, Inc. RVMDNCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinomaactive not recruiting500

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.